1 / 27

SEVERE SEPSIS&SEPTIC SHOCK IN PEDIATRICS.

Abdel Razzaq Abu Mayaleh, MD PRCS _ New Hospital - Hebron Based partially on www.picucourse.org. SEVERE SEPSIS&SEPTIC SHOCK IN PEDIATRICS. INTRODUCTION. SEPSIS :- it’s an infection plus systemic manifestation of infection.

gordy
Download Presentation

SEVERE SEPSIS&SEPTIC SHOCK IN PEDIATRICS.

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Abdel Razzaq Abu Mayaleh, MD PRCS _ New Hospital - Hebron Based partially onwww.picucourse.org SEVERE SEPSIS&SEPTIC SHOCK IN PEDIATRICS.

  2. INTRODUCTION • SEPSIS:- it’s an infection plus systemic manifestation of • infection. • SEVERE SEPSIS :- Sepsis plus sepsis-induced organ • dysfunction or tissue hypo perfusion. • SEPTIC SHOCK:- sepsis-induced hypotension persisting • despite adequate fluid resuscitation and elevated lactate. • HYPOTENTION:- S.BP < 70 + 2 ×wt. • (80 + 2 × wt) • SHOCK:-DO2 < VO2 . . .

  3. A clinician, armed with the sepsis bundles, attacks the three heads of severe sepsis: hypotension, hypoperfusion and organ dysfunction. Crit Care Med 2004; 320(Suppl):S595-S597

  4. Septic Shock Epidemiology • During the last 2 decades the incidence of sepsis & septic shock has increased across all age groups. This is thought to be due to: • ↑ use of invasive procedures • ↑ use of immunosuppressive drugs • ↑ microbacterial ressistance • Child mortality improved dramatically from 97% → 9% due to the advance in critical care technology.

  5. Septic Shock: “Warm Shock” • Early, compensated, hyperdynamic state • Clinical signs • Warm extremities with bounding pulses, tachycardia, tachypnea, confusion. • Physiologic parameters • widened pulse pressure, increased cardiac ouptut and mixed venous saturation, decreased systemic vascular resistance. • Biochemical evidence: • Hypocarbia, elevated lactate, hyperglycemia

  6. Septic Shock: “Cold Shock” • Late, uncompensated stage with drop in cardiac output. • Clinical signs • Cyanosis, cold and clammy skin, rapid, thready pulses, shallow respirations. • Physiologic parameters • Decreased mixed venous sats, cardiac output and CVP, increased SVR, thrombocytopenia, oliguria, myocardial dysfunction, capillary leak • Biochemical abnormalities • Metabolic acidosis, hypoxia, coagulopathy, hypoglycemia.

  7. MANAGEMENT-GENERAL • Goal: increase oxygen delivery and decrease oxygen demand: • Oxygen • Fluid • Temperature control • Antibiotics • Correct metabolic abnormalities • Spare WOB ? • Inotropes DO2 = C.O. x CaO2 Hg X SatO2 X 1.34 . VO2 (O2 Extraction) septic . . normal . DO2

  8. Fluid Resuscitation • Aggressive fluid resuscitation with boluses of 20 ml/kg over 5-10 min • Blood pressure by itself is not a reliable endpoint for resuscitation • Initial resuscitation usually requires 40-60 ml/kg, but more may be required

  9. Therapeutic Endpoints • Capillary refill < 2 sec • Warm extremities • Urine output > 1 ml/kg/hr • Normal mental status • Decreased lactate • Central venous O2 saturation > 70%

  10. Hemodynamic Support • Hemodynamic profile may be variable • Dopamine for hypotension • Epinephrine or norepinephrine for dopamine-refractory shock • Dobutamine for low cardiac output state • Inhaled NO useful in neonates with post-partum pulmonary hypertension and sepsis

  11. Other Therapies • Steroids: recommended for children with catecholamine resistance and suspected or proven adrenal insufficiency. • Activated protein C not studied adequately in children yet. • GM-CSF shown to be of benefit in neonates with sepsis and neutropenia. • Extracorporeal membrane oxygenation (ECMO) may be considered in children with refractory shock or respiratory failure.

  12. 2005 Shock ABC FLUID BOLUS-20-60cc/kg Dopamine/ dobutamine Cold shock Warm shock NE NE EPI steroids Milrinone

  13. 0 min 5 min Recognize decreased mental status and perfusion.Maintain airway and establish access according to PALS guidelines. Push 20 cc/kg isotonic saline or colloid boluses up and over 60 cc/kg. Correct hypoglycemia and hypocalcaemia. Administer antibiotics. 15 min Fluid refractory shock * * Establish central Venous access, begin dopamine or dobutamine therapy and establish arterial monitoring . Fluid responsive * Fluid refractory – dopamine/ dobutamine resistant shock Titrate epinephrine for cold shock, norepinephrine for warm shock to normal clinical endpoints and ScvO2 saturation ≥70% . Observe in PICU

  14. Catecholamine-resistant shock Begin hydrocortisone if at risk for absolute adrenal insufficiency 60 min Normal Blood Pressure Cold Shock ScvO2 Sat <70% Low Blood Pressure Cold Shock ScvO2 Sat < 70% Low Blood pressure Warm Shock ScvO2 Sat ≥ 70% Add Vasodilator or type III phosphodiesgerase inhibitor with volume loading Titrate volume and epinephrine Titrate volume and norepinephrine Persistent Catecholamine- resistant shock Start Cardiac output measurement and direct fluid, inotrope, vasopressor, vasodilator, and hormonal therapies to attain CL>3.3 and <6.0 L/min/m² Refractory shock Consider ECMO

  15. VENTILATOR MANAGEMENT • Assist control mode-volume ventilation • Reduce tidal volume to 6ml/kg predicted body wt. • Keep Pplat <30cm H2O • Maintain SaO2 / pO2 88-95% • Anticipated PEEP setting at various FiO2 requirements • FiO2 0.3 0.4 0.5 0.5 0.6 0.7 0.8 0.9 1.0 • PEEP 5 5 8 10 12 14 16 18 20

  16. Sedation and Analgesia in Sepsis • Sedation protocol for mechanically ventilated patients with standardized subjective sedation scale target. • Intermittent bolus • Continuous infusion with daily awakening/retitration Grade B Kollef, et al. Chest 1998; 114:541-548 Brook, et al. CCM 1999; 27:2609-2615 Kress, et al. NEJM 2000; 342:1471-1477

  17. Neuromuscular Blockers • Avoid if possible • Used longer than 2-3 hrs • PRN bolus • Continuous infusion with twitch monitor Grade E

  18. 100 96 Intensive treatment 92 P=0.01 In-hospital survival (%) 88 Conventional treatment 84 80 0 0 50 100 150 200 250 Days after admission The Role of IntensiveInsulin Therapy in the Critically Ill • At 12 months, intensive insulin therapy reduced mortality by 3.4% (P<0.04) Adapted from Figure 1B, page 1363, with permission from van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in critically ill patients. N Engl J Med 2001;345:1359-67

  19. Glucose Control • After initial stabilization • Glucose < 150 mg/dL • Continuous infusion insulin and glucose or feeding (enteral preferred) • Monitoring • Initially q30–60 mins • After stabilization q4h Grade D

  20. Bicarbonate Therapy • Bicarbonate therapy not recommended to improve hemodynamics in patients with lactate induced pH >7.15 • Grade C • Cooper, et al. Ann Intern Med 1990; 112:492-498 • Mathieu, et al. CCM 1991; 19:1352-1356

  21. Primary Stress Ulcer Risk Factors Frequently Present in Severe Sepsis • Mechanical ventilation • Coagulopathy • Hypotension

  22. Choice of Agents forStress Ulcer Prophylaxis • H2 receptor blockers • Role of proton pump inhibitors Grade C Cook DJ, et al. Am J Med 1991; 91:519-527

  23. Blood Product AdministrationRed Blood Cells Tissue hypoperfusion resolved No extenuating circumstances • Coronary artery disease • Acute hemorrhage • Lactic acidosis Transfuse < 7.0 g/dl to maintain 7.0-9.0 g/dL Grade B

  24. Blood Product Administration • Do not use erythropoietin to treat sepsis-related anemia. Erythropoietin may be used for other accepted reasons. Grade B

  25. Blood Product Administration • Fresh frozen plasma • Bleeding • Planned invasive procedures. • Grade E

  26. Blood Product Administration • Do not use antithrombin therapy. • Grade B Warren et al. JAMA 2001; 1869-1878

  27. Blood Product Administration • Platelet administration • Transfuse for < 5000/mm3 - • Transfuse for 5000/mm3 – 30,000/mm3 with significant bleeding risk • Transfuse < 50,000/mm3 for invasive procedures or bleeding Grade E

More Related